AU2022202825B1 - Polypeptide, polypeptide composition and application, and prepared anti-wrinkle lotion thereof - Google Patents
Polypeptide, polypeptide composition and application, and prepared anti-wrinkle lotion thereof Download PDFInfo
- Publication number
- AU2022202825B1 AU2022202825B1 AU2022202825A AU2022202825A AU2022202825B1 AU 2022202825 B1 AU2022202825 B1 AU 2022202825B1 AU 2022202825 A AU2022202825 A AU 2022202825A AU 2022202825 A AU2022202825 A AU 2022202825A AU 2022202825 B1 AU2022202825 B1 AU 2022202825B1
- Authority
- AU
- Australia
- Prior art keywords
- polypeptide
- parts
- glu
- composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 159
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 155
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 155
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 35
- 239000006210 lotion Substances 0.000 title claims abstract description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 9
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 8
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- 229940106189 ceramide Drugs 0.000 claims description 8
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 229960001631 carbomer Drugs 0.000 claims description 7
- 229940119170 jojoba wax Drugs 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000000337 buffer salt Substances 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 150000002895 organic esters Chemical class 0.000 claims description 3
- 230000037380 skin damage Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 abstract description 18
- 230000037303 wrinkles Effects 0.000 abstract description 18
- 102000008186 Collagen Human genes 0.000 abstract description 10
- 108010035532 Collagen Proteins 0.000 abstract description 10
- 229920001436 collagen Polymers 0.000 abstract description 10
- 230000032683 aging Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 230000004663 cell proliferation Effects 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 210000004207 dermis Anatomy 0.000 abstract description 5
- 238000007254 oxidation reaction Methods 0.000 abstract description 5
- 206010033675 panniculitis Diseases 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 210000000434 stratum corneum Anatomy 0.000 abstract description 5
- 210000004304 subcutaneous tissue Anatomy 0.000 abstract description 5
- 239000013589 supplement Substances 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GCYFUZJHAXJKKE-KKUMJFAQSA-N Glu-Arg-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GCYFUZJHAXJKKE-KKUMJFAQSA-N 0.000 description 1
- ZWMYUDZLXAQHCK-CIUDSAMLSA-N Glu-Met-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O ZWMYUDZLXAQHCK-CIUDSAMLSA-N 0.000 description 1
- JDAWAWXGAUZPNJ-ZPFDUUQYSA-N Ile-Glu-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JDAWAWXGAUZPNJ-ZPFDUUQYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241001435619 Lile Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- WBZOZLNLXVBCNW-LTHWPDAASA-N Trp-Thr-Ile Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)O)=CNC2=C1 WBZOZLNLXVBCNW-LTHWPDAASA-N 0.000 description 1
- YDPFWRVQHFWBKI-GVXVVHGQSA-N Val-Glu-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YDPFWRVQHFWBKI-GVXVVHGQSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention discloses a polypeptide and a polypeptide composition and an
application, and a prepared anti-wrinkle lotion thereof, belonging to the field of biotechnology.
The present invention includes a polypeptide 1 or a polypeptide 2; the polypeptide 1 has the
following sequence: Ala-Glu-Lys-Glu-Met-Asp-Glu-Arg-Tyr (SEQ ID NO:1), and the polypeptide
2 has the following sequence: Trp-Thr-le-Val-Glu-His-Ile-Glu-Arg-Leu-Asn (SEQ ID NO:2). The
two polypeptides of the present invention have a preferable effect of promoting the secretion of
collagen; meanwhile, with smaller molecular weight, the two polypeptides can penetrate
through stratum corneum freely to enhance the cell vitality of dermis, promote the cell
proliferation, supplement and repair the lost collagen on the surface of skin such that
subcutaneous tissues become strengthened to rapidly heal the damages (for example, from
ultraviolet ray or oxidization), thus achieving the purposes of wrinkle removal and aging
resistance. Moreover, the combination of the polypeptide 1 and the polypeptide 2 has a
synergistic effect.
Description
Polypeptide, Polypeptide Composition and Application, and Prepared Anti-Wrinkle Lotion Thereof
Technical Field
The present invention relates to the field of biotechnology, and in particular to a polypeptide and a polypeptide composition and an application, and a prepared anti-wrinkle lotion thereof.
Background
The anti-wrinkle and anti-aging has been one of the hot topics in medical science, and the top priority in cosmetics industry. Based on the market survey of cosmetics in the United States, the moisturizing and anti-wrinkle products have accounted for more than half of the market shares in the commercially available cosmetics. With the increase of the proportion in the domestic aging population, the demand for moisturizing and anti-wrinkle skin care products is increasingly growing.
The appearance of wrinkle is the symbol of skin aging; skin aging is a part of aging of body; the aging of body is reflected in skin most obviously. Aging is a kind of natural law, but is influenced by other factors such as, living habit, ultraviolet ray, frequently exaggerated expression, lack of exercises, dry skin due to lack of water, environmental and psychological factors.
At present, there are various types of moisturizing and anti-wrinkle products in the cosmetics market. But the durable-slow release effect is far from the expected effect; moreover, the frequent use of such kind of product will cause burdens on skin and wastes of the active ingredients. Therefore, the exploration on the durable release of moisturizing and anti-wrinkle active ingredients becomes the key point to overcome the shortcomings of the existing moisturizing and anti-wrinkle products.
Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of the common general knowledge in the field.
It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.
Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".
Summary
According to a first aspect, the present invention provides an isolated polypeptide, comprising a polypeptide 1, wherein the polypeptide 1 has the following sequence: Ala-Glu-Lys-Glu-Met Asp-Glu-Arg-Tyr (SEQ ID NO:1).
According to a second aspect, the present invention provides a polypeptide composition,
comprising the polypeptide 1 of the first aspect and a polypeptide 2, wherein the polypeptide
2 has the following sequence: Trp-Thr-le-Val-Glu-His-le-Glu-Arg-Leu-Asn (SEQ ID NO:2).
According to a third aspect, the present invention provides a composition, comprising the
polypeptide 1 of the first aspect and a polypeptide 2, and a dispersion carrier, wherein the
polypeptide 2 has the following sequence: Trp-Thr-le-Val-Glu-His-le-Glu-Arg-Leu-Asn (SEQ ID NO:2).
According to a fourth aspect, the present invention provides a composition, comprising the composition of the third aspect and at least an effective amount of an active pharmaceutical ingredient for treating skin damage.
According to a fifth aspect, the present invention provides a use of the polypeptide of the first aspect or the polypeptide composition of the second aspect in the preparation of a skin care product for external use.
According to a sixth aspect, the present invention provides an anti-wrinkle lotion, wherein the anti-wrinkle lotion is prepared by the following raw materials according to parts by weight: 0.5 1 parts of the polypeptide composition of claim 3, 2-5 parts of jojoba oil, 3-4 parts of isopropyl myristate, 2-4 parts of PEG-7 glyceryl cocoate, 10-15 parts of lecithin, 5-7 parts of carbomer, 5-7 parts of glycerin, 3-5 parts of propylene glycol, 1-2 parts of PEG-400, 0.5-1 parts of sodium hyaluronate, 0.5-1 parts of ceramide, 0.05-1 parts of citric acid and 30-60 parts of deionized water.
An aspect of the present invention is to provide a polypeptide, a polypeptide composition and an application, and a prepared anti-wrinkle lotion thereof. The polypeptides of the present invention have a preferable effect of promoting the secretion of collagen; meanwhile, with smaller molecular weight, the polypeptides can penetrate through stratum corneum freely to enhance the cell vitality of dermis, promote the cell proliferation, supplement and repair the
la lost collagen on the surface of skin such that subcutaneous tissues become strengthened to rapidly lb heal the damages (for example, from ultraviolet ray or oxidization), thus achieving the purposes of wrinkle removal and aging resistance. Moreover, the combination of the polypeptide 1 and the polypeptide 2 has a synergistic effect.
The technical solution of the present invention is achieved as follows:
The present invention provides a polypeptide, including a polypeptide 1 and a polypeptide 2; the polypeptide 1 has the following sequence: Ala-Glu-Lys-Glu-Met-Asp-Glu-Arg-Tyr (SEQ ID NO:1), and the polypeptide 2 has the following sequence: Trp-Thr-Ile-Val-Glu-His-le-Glu-Arg-Leu-Asn (SEQ ID NO:2).
The present invention further seeks to protect a polypeptide composition, including the above polypeptide 1 and polypeptide 2.
As a further improvement of the present invention, a mass ratio of the polypeptide 1 to the polypeptide 2 is (3-5):1.
The present invention further seeks to protect a polypeptide derivative, where the polypeptide derivative is a modified product of the above polypeptide 1 or polypeptide 2.
The present invention further seeks to protect a polypeptide derivative composition, where the polypeptide derivative composition includes modified products of the above polypeptide 1 and polypeptide 2 having a mass ratio of (2-7):1.
The present invention further protects a composition, including at least one of the above polypeptide 1 and polypeptide 2, a composition of at least one of the modified products of the above polypeptide 1 and polypeptide 2, and a dispersion carrier.
As a further improvement of the present invention, the dispersion carrier includes one or more of water, a buffer salt solution, a fatty alcohol, a solid wax, ethylene glycol, glycerin or an organic ester.
The present invention further seeks to protect a composition, including the above composition, and at least an effective amount of an active pharmaceutical ingredient for treating a certain disease.
The present invention further seeks to protect an application of the above polypeptide or the above polypeptide composition or the above polypeptide derivative or the above polypeptide derivative composition in the preparation of a skin care product for external use.
The present invention further seeks to protect an anti-wrinkle lotion, where the anti-wrinkle lotion is prepared by the following raw materials according to parts by weight: 0.5-1 parts of the above polypeptide composition, 2-5 parts of jojoba oil, 3-4 parts of isopropyl myristate, 2-4 parts of PEG-7 glyceryl cocoate, 10-15 parts of lecithin, 5-7 parts of carbomer, 5-7 parts of glycerin, 3-5 parts of propylene glycol, 1-2 parts of PEG-400, 0.5-1 parts of sodium hyaluronate, 0.5-1 parts of ceramide, 0.05-1 parts of citric acid and 30-60 parts of deionized water.
The present invention has one or more of the following beneficial effects: the present invention provides a novel polypeptide sequence and a polypeptide composition, including a polypeptide 1 and a polypeptide 2; such two polypeptides could produce better effect in promoting the secretion of collagen. Meanwhile, with smaller molecular weight, the two polypeptides can penetrate through stratum corneum freely to enhance the cell vitality of dermis, promote the cell proliferation, supplement and repair the lost collagen on the surface of skin such that subcutaneous tissues become strengthened to rapidly heal the damages (for example, from ultraviolet ray or oxidization), thus achieving the purposes of wrinkle removal and aging resistance. Moreover, the combination of the polypeptide 1 and the polypeptide 2 has a synergistic effect.
The anti-wrinkle lotion prepared in the present invention contains emollient ingredients, including glycerin, propylene glycol and PEG-400 and thus, has good spreadability on skin. The anti-wrinkle lotion forms a layer of film on the surface to achieve moistening and moisturizing effects. Meanwhile, sodium hyaluronate, ceramide and polypeptide composition are infiltrated into the inside of skin to be released slowly, thereby further exerting the moistening and moisturizing effects for a long time. The product of the present invention is steady and has long service life, simple preparation method and low production costs.
Detailed Description of the Embodiments
The technical solution in the examples of the present invention will be described clearly and integrally; obviously, the examples described herein are merely partial, but not all examples of the present invention. Based on the examples of the present invention, all the other examples obtained by a person skilled in the art without making inventive effort shall fall within the protection scope of the present invention.
The inventor of the present invention extracted active proteins from plants having cosmetic efficacy to obtain dozens of functional polypeptides by multi-step enzymolysis and screening.
An example of the present invention further provides a polypeptide, including a polypeptide 1 and a polypeptide 2; the polypeptide 1 has the following sequence: Ala-Glu-Lys-Glu-Met-Asp-Glu-Arg-Tyr (SEQ ID NO:1); the polypeptide 2 has the following sequence: Trp-Thr-le-Val-Glu-His-le-Glu-Arg-Leu-Asn (SEQ ID NO:2).
The polypeptide is a short peptide, and has a preferable effect of promoting the secretion of collagen and can be absorbed better. Meanwhile, with smaller molecular weight, the short peptide can penetrate through stratum corneum freely to enhance the cell vitality of dermis, promote the cell proliferation, supplement and repair the lost collagen on the surface of skin such that subcutaneous tissues become strengthened to rapidly heal the damages (for example, from ultraviolet ray or oxidization), thus achieving the purposes of wrinkle removal and aging resistance.
As commonly known by a person skilled in the art, in the above polypeptides, the amino acid represented by each abbreviation of the amino acid is show in Table 1:
Table 1
Name Symbol or abbreviation
Alanine A or Ala
Aspartic acid D or Asp
Arginine R or Arg
Asparagine N or Asn
Glutamic acid E or Glu
Lysine K or Lys
Methionine M or Met
Tyrosine Y or Tyr
Tryptophan W or Trp
Threonine T or Thr
Isoleucine I or lIle
Valine V or Val
Histidine H or His
Leucine L or Leu
A further example of the present invention provides a polypeptide composition, including a polypeptide 1 and a polypeptide 2 with a mass ratio of (3-5):1.
A further example of the present invention provides a polypeptide derivative, where the polypeptide derivative is a modified product based on the above polypeptide 1 or polypeptide 2.
The term "derivative" used herein refers to a variant of a reference molecule, e.g., a polypeptide. For example, the derivative of polypeptide may include a variant where one or two amino acids are substituted relative to the reference polypeptide, preferably, the derivative of polypeptide is a sequence derived from conservative substitution. The derivative may further relate to the polypeptide modified with or by, including but not limited to non-natural amino acids, D- amino acids, amino acids modified at amino and/or carboxyl terminals (N- or C-terminal), especially for the modifications of the amino at N-terminal and/or the carboxyl at C-terminal, fatty acid modifications, peptide mimics, pseudopeptides and other similar kinds of modified products.
As described herein, the polypeptide of the present invention may form polypeptide derivatives via modification. As described herein, the polypeptide of the present invention may form polypeptide derivatives via modification. The polypeptide of the present invention or derivatives thereof may be prepared by the method known by a person skilled in the art very well, including the well-known chemical synthesis method.
Specifically, the conservative variation sequence of the present invention refers to the sequence obtained by the conservative substitution of one or two amino acids, where the conservative substitution refers that a specified amino acid is substituted by another amino acid with similar properties. For example, examples which may be regarded as the conservative substitution (similar properties) include but not limited to:
a) alanine, serine and threonine
b) glutamic acid and aspartic acid;
c) asparagine and glutamine;
d) arginineand lysine;
e) isoleucine , leucine, methionine and; f) phenylalanine, tyrosine and tryptophan.
A further example of the present invention provides a polypeptide derivative composition, including modified products of the above polypeptide 1 and polypeptide 2 having a mass ratio of (2-7):1.
A further example of the present invention provides a composition, including at least one of the above polypeptide 1 and polypeptide 2, a composition of at least one of the modified products of the above polypeptide 1 and polypeptide 2, and a dispersion carrier. The dispersion carrier includes one or more of water, a buffer salt solution, a fatty alcohol, a solid wax, ethylene glycol, glycerin or an organic ester. The polypeptide is subjected to dispersion and liquidation by the dispersion carrier to be suitable for the field of cosmetics or skin care products especially, thus being capable of improving the contact adhesion and permeability thereof with skin.
A further example of the present invention provides a composition, including the above composition, and at least an effective amount of an active pharmaceutical ingredient for treating a certain disease.
The polypeptide has shorter chain segments by itself and thus, has better absorbable properties. The composition is in combination with the active pharmaceutical ingredients for treating skin damage to promote the exertion of the efficacy, thus improving the efficacy obviously.
A further example of the present invention further provides an application of the polypeptide or the polypeptide composition or the polypeptide derivative or the polypeptide derivative composition mentioned above in the preparation of a skin care product for external use.
Example 1
An anti-wrinkle lotion was prepared by the following raw materials according to parts by weight: 0.5 parts of polypeptide composition, 2 parts of jojoba oil, 3 parts of isopropyl myristate, 2 parts of PEG-7 glyceryl cocoate, 10 parts of lecithin, 5 parts of carbomer, 5 parts of glycerin, 3 parts of propylene glycol, 1 part of PEG-400, 0.5 parts of sodium hyaluronate, 0.5 parts of ceramide, 0.05 parts of citric acid and 30 parts of deionized water. The polypeptide composition included a polypeptide 1 and a polypeptide 2; and a mass ratio of the polypeptide 1 to the polypeptide 2 was 3:1.
Preparation method:
(1) lecithin, carbomer, glycerin, propylene glycol and PEG-400 were stirred and mixed, and subjected to ultrasonic treatment for 10 min at 300 W to form an emulsifier;
(2) the polypeptide composition, jojoba oil, isopropyl myristate, and PEG-7 glyceryl cocoate were mixed evenly, and heated up to 35°C to form an oil phase;
(3) sodium hyaluronate and ceramide were mixed with 1/3 deionized water evenly to form an aqueous phase;
(4) citric acid was added to the remaining deionized water to obtain a pH adjusting agent;
(5) the oil phase in the step (2) and the emulsifier in the step (1) were stirred and mixed, and dropwise added with the aqueous phase in the step (3), then added with the pH adjusting agent obtained in the step (4) at a stirring condition of 1000 r/min, and stirred continuously for h to obtain the anti-wrinkle lotion.
Example 2
An anti-wrinkle lotion was prepared by the following raw materials according to parts by weight: 1 part of polypeptide composition, 5 parts of jojoba oil, 4 parts of isopropyl myristate, 4 parts of PEG-7 glyceryl cocoate, 15 parts of lecithin, 7 parts of carbomer, 7 parts of glycerin, 5 parts of propylene glycol, 2 parts of PEG-400, 1 part of sodium hyaluronate, 1 part of ceramide, 1 part of citric acid and 60 parts of deionized water. The polypeptide composition included a polypeptide 1 and a polypeptide 2; and a mass ratio of the polypeptide 1 to the polypeptide 2 was 5:1.
The preparation method was substantially the same as that of Example 1.
Example 3
An anti-wrinkle lotion was prepared by the following raw materials according to parts by weight: 0.7 parts of polypeptide composition, 3.5 parts of jojoba oil and 3.5 parts of isopropyl myristate, 3 parts of PEG-7 glyceryl cocoate, 12 parts of lecithin, 6 parts of carbomer, 6 parts of glycerin, 4 parts of propylene glycol, 1.5 parts of PEG-400, 0.7 parts of sodium hyaluronate, 0.7 parts of ceramide, 0.2 parts of citric acid and 45 parts of deionized water. The polypeptide composition included a polypeptide 1 and a polypeptide 2; and a mass ratio of the polypeptide 1 to the polypeptide 2 was 4:1.
The preparation method was substantially the same as that of Example 1.
Comparative Example 1
Compared with Example 3, the polypeptide composition was replaced by polypeptide 1; and the others were the same.
Comparative Example 2
Compared with Example 3, the polypeptide composition was replaced by polypeptide 2; and the others were the same.
Comparative Example 3
Compared with Example 3, the polypeptide composition was replaced by an anti-wrinkle active ingredient, coenzyme Q10; and the others were the same.
Test Example 1: Stability test
mL of the anti-wrinkle lotions prepared in Examples 1-3 and Comparative Examples 1-3 were divided into 3 parts, each 10 ml was put to a sealed glass bottle, then respectively placed at 4°C, 25°C and 50°C for half a year, and sampling was performed respectively in January, March and June for observation; these lotions kept a steady state, free of a separated layer or precipitate.
Physical properties (including refractive index, pH value, viscosity, electrical conductivity and surface tension) of the anti-wrinkle lotions prepared in Examples 1-3 and Comparative Examples 1-3 were determined; the refractive index was determined by an Abbe refractometer; the pH value was determined by a pH meter; the viscosity was determined by a Brookfield viscometer; the electrical conductivity was determined by a conductometer; the surface tension was determined by a surface tension meter; all the samples were determined at 25°C and a humidity of 65%. The results are shown in Table 2.
Table 2
Group Refractive pH value Viscosity Electrical Surface tension index (nd) (mPa.s) conductivity (mN/m) (pS/cm)
Example 1 1.452 6.54 5.5 175.2 37.25
Example 2 1.455 6.47 5.3 174.7 36.78
Example 3 1.457 6.42 5.1 174.0 35.77
Comparati 1.324 6.21 6.7 193.5 40.21 ve
Example 1
Comparati 1.352 6.15 6.5 189.7 41.25 ve Example 2
Comparati 1.310 6.10 7.2 210.3 43.17 ve Example 3
It can be seen from Table 2 that the anti-wrinkle lotion of the present invention has good physical properties, a weak-acidity pH value close to a pH value of human skin, low viscosity and small surface tension, indicating that the anti-wrinkle lotion is easy to be spread out on skin.
Test Example 2: Effect test
60 women aged 36-52 were selected and divided into 6 groups, 10 women each group; the anti-wrinkle lotions prepared in Examples 1-3 and Comparative Examples 1-3 were applied to the women of the 6 groups continuously for 30 d on trial, thus performing comparison, analysis and evaluation on the anti-wrinkle effects of the anti-wrinkle lotions. The anti-wrinkle effects are the improvement conditions of facial wrinkles, eye wrinkles, forehead wrinkles, fine wrinkles and skin elasticity. The results are shown in Table 3.
Table 3
Group Improvement Improvement Improvement Improvement Improvement rate of facial rate of eye rate of rate of fine rate of skin wrinkles(%) wrinkles(%) forehead wrinkles(%) elasticity(%) wrinkles (%)
Slight Obvious Slight Obvious Slight Obvious Slight Obvious Slight Obvious
Example 1 30 70 30 70 40 60 10 90 40 60
Example 2 20 80 20 80 30 70 10 90 30 70
Example 3 20 80 20 80 20 80 0 100 20 80
Comparative 40 60 40 60 50 50 40 60 40 60 Example 1
Comparative 50 50 50 50 50 50 60 40 50 50 Example 2
Comparative 70 30 70 30 80 20 70 30 80 20 Example 3
It can be seen from the above table that the anti-wrinkle lotion prepared in the present invention has an obvious anti-wrinkle effect, and can obviously improve the facial wrinkles, eye wrinkles, forehead wrinkles and fine wrinkles and strengthen skin elasticity. Either of the two polypeptides of the present invention have a better effect in promoting the secretion of collagen; meanwhile, with smaller molecular weight, the two polypeptides can penetrate through stratum corneum freely to enhance the cell vitality of dermis, promote the cell proliferation, supplement and repair the lost collagen on the surface of skin, such that subcutaneous tissues become strengthened to rapidly heal the damages (for example, from ultraviolet ray or oxidization), thus achieving the purposes of wrinkle removal and aging resistance. Moreover, the combination of the polypeptide 1 and the polypeptide 2 could produce a synergistic effect.
What is described above are merely preferred examples of the present invention, but are not construed as limiting the present invention. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present invention shall fall within the protection scope of the present invention.
SEQUENCE LISTING 28 Apr 2022
<110> AUSTRALIAN HEALTH INDUSTRY CO. PTY LTD
<120> Polypeptide, Polypeptide Composition and Application, and Prepared Anti-Wrinkle Lotion Thereof
<130> SG
<160> 2 2022202825
<170> PatentIn version 3.5
<210> 1 <211> 9 <212> PRT <213> Artificial Sequence
<220> <223> peptide 1
<400> 1
Ala Glu Lys Glu Met Asp Glu Arg Tyr 1 5
<210> 2 <211> 11 <212> PRT <213> Artificial Sequence
<220> <223> peptide 2
<400> 2
Trp Thr Ile Val Glu His Ile Glu Arg Leu Asn 1 5 10
Page 1
Claims (8)
1. An isolated polypeptide, comprising a polypeptide 1, wherein the polypeptide 1 has the following sequence: Ala-Glu-Lys-Glu-Met-Asp-Glu-Arg-Tyr (SEQ ID NO:1).
2. A polypeptide composition, comprising the polypeptide 1 of claim 1 and a polypeptide 2, wherein the polypeptide 2 has the following sequence: Trp-Thr-le-Val-Glu-His-le-Glu-Arg Leu-Asn (SEQ ID NO:2).
3. The polypeptide composition according to claim 2, wherein a mass ratio of the polypeptide 1 to the polypeptide 2 is (3-5):1.
4. A composition, comprising the polypeptide 1 of claim 1 and a polypeptide 2, and a dispersion carrier, wherein the polypeptide 2 has the following sequence: Trp-Thr-le-Val-Glu-His-le Glu-Arg-Leu-Asn (SEQ ID NO:2).
5. The composition according to claim 4, wherein the dispersion carrier comprises one or more of water, a buffer salt solution, a fatty alcohol, a solid wax, ethylene glycol, glycerin or an organic ester.
6. A composition, comprising the composition of claim 4 and at least an effective amount of an active pharmaceutical ingredient for treating skin damage.
7. Use of the polypeptide of claim 1 or the polypeptide composition of claim 2 in the preparation of a skin care product for external use.
8. An anti-wrinkle lotion, wherein the anti-wrinkle lotion is prepared by the following raw materials according to parts by weight: 0.5-1 parts of the polypeptide composition of claim 3, 2-5 parts of jojoba oil, 3-4 parts of isopropyl myristate, 2-4 parts of PEG-7 glyceryl cocoate, -15 parts of lecithin, 5-7 parts of carbomer, 5-7 parts of glycerin, 3-5 parts of propylene glycol, 1-2 parts of PEG-400, 0.5-1 parts of sodium hyaluronate, 0.5-1 parts of ceramide, 0.05 1 parts of citric acid and 30-60 parts of deionized water.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022202825A AU2022202825B1 (en) | 2022-04-28 | 2022-04-28 | Polypeptide, polypeptide composition and application, and prepared anti-wrinkle lotion thereof |
CN202210501410.9A CN114920801B (en) | 2022-04-28 | 2022-05-09 | Polypeptide, polypeptide composition and application thereof, and wrinkle-removing emulsion prepared by polypeptide composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022202825A AU2022202825B1 (en) | 2022-04-28 | 2022-04-28 | Polypeptide, polypeptide composition and application, and prepared anti-wrinkle lotion thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2022202825B1 true AU2022202825B1 (en) | 2023-09-07 |
Family
ID=82809108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022202825A Active AU2022202825B1 (en) | 2022-04-28 | 2022-04-28 | Polypeptide, polypeptide composition and application, and prepared anti-wrinkle lotion thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114920801B (en) |
AU (1) | AU2022202825B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002050289A1 (en) * | 2000-12-19 | 2002-06-27 | Sembiosys Genetics, Inc. | Methods for the production of multimeric proteins, and related compositions |
WO2019027364A1 (en) * | 2017-07-31 | 2019-02-07 | Biopetrolia Ab | Fungal cell with improved protein production capacity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1388339A1 (en) * | 2002-08-06 | 2004-02-11 | Naina Sachdev | Alkaline anti-wrinkle composition comprising carnosine |
JP2007246461A (en) * | 2006-03-17 | 2007-09-27 | Kozo Tsubouchi | Production and utilization of transdermally absorbable low molecular silk peptide having cell growth-promoting function |
CN103405379B (en) * | 2013-07-29 | 2015-11-04 | 广州丹奇日用化工厂有限公司 | A kind ofly be rich in amino acid whose cosmetic composition and the application in skin care item thereof |
CN104523554A (en) * | 2014-11-20 | 2015-04-22 | 彩虹之巅电子商务(上海)有限公司 | Anti-wrinkle moisture-retention skin care product containing bioactive peptide ingredient |
JP7296642B2 (en) * | 2018-02-27 | 2023-06-23 | リポトゥルー,エセ.エレ. | Peptides and compositions for cosmetic and pharmaceutical use |
CN111961119B (en) * | 2020-09-02 | 2021-03-12 | 方晓东 | Application of polypeptide in preparation of medicine or cosmetic for promoting collagen secretion |
-
2022
- 2022-04-28 AU AU2022202825A patent/AU2022202825B1/en active Active
- 2022-05-09 CN CN202210501410.9A patent/CN114920801B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002050289A1 (en) * | 2000-12-19 | 2002-06-27 | Sembiosys Genetics, Inc. | Methods for the production of multimeric proteins, and related compositions |
WO2019027364A1 (en) * | 2017-07-31 | 2019-02-07 | Biopetrolia Ab | Fungal cell with improved protein production capacity |
Also Published As
Publication number | Publication date |
---|---|
CN114920801A (en) | 2022-08-19 |
CN114920801B (en) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101541831B (en) | Neuronal exocytosis inhibiting peptides | |
US8435950B2 (en) | Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same | |
US9393186B2 (en) | Synthetic peptides useful in the treatment of the skin and use thereof in cosmetic or dermopharmaceutical compositions | |
CN112043621B (en) | Preservative-free polypeptide composition with anti-aging effect | |
KR101933685B1 (en) | Drug Coated Microneedle and Manufacturing Method Thereof | |
KR101865837B1 (en) | Cosmetic composition for improving skin wrinkle having instantly unwrinkling effect | |
MX2007012504A (en) | Dermopharmaceutical or cosmetic composition comprising enkephalin-derived peptides for reducing and/or eliminating facial wrinkles. | |
KR101889322B1 (en) | Peptide for improving skin wrinkle and anti-aging effect, and uses thereof | |
KR102077983B1 (en) | Composition for improving skin wrinkles and skin whitening | |
CN113631566A (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
CN113648239A (en) | Oligonucleotide skin care preparation synthesized by polyprotein and oligopeptide and having anti-wrinkle repairing effect | |
CN102988193A (en) | Medical beautifying polypeptide capable of promoting cell regeneration and delaying skin aging | |
KR101831977B1 (en) | A peptide having activity of Epidermal growth factor activity and production method therefor | |
CN102498128B (en) | Peptide having activity of transforming growth factor and production method therefor | |
JP5858482B2 (en) | Novel anti-aging peptides that modulate survivin and compositions containing the same | |
AU2022202825B1 (en) | Polypeptide, polypeptide composition and application, and prepared anti-wrinkle lotion thereof | |
CN109730943A (en) | A kind of anti-wrinkle composition | |
CN107400160B (en) | Anti-relaxing, anti-firming peptides and cosmetic products containing the same | |
KR102281606B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex | |
US8809279B2 (en) | Peptides that are modulators of the protein TRF2 and compositions containing same | |
KR102160566B1 (en) | Conjugate of minoxidil and peptide | |
AU2017399481B2 (en) | Conjugate of salicylic acid and peptide | |
JP6300329B2 (en) | Polypeptides expressed in the stratum corneum and uses thereof | |
KR102016658B1 (en) | Conjugate of salicylic acid and peptide | |
Kumar et al. | Proteins and Peptides in Personal Care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |